Biogen Idec to acquire Syntonix Pharmaceuticals
Biogen Idec (NASDAQ:BIIB) and Syntonix Pharmaceuticals today announced that the companies have signed a definitive agreement for the acquisition of Syntonix by Biogen Idec. Syntonix, a privately held biopharmaceutical company focused on discovering and developing long-acting therapeutic products to improve treatment regimens for chronic diseases, has multiple pre-clinical programs in hemophilia.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.